Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/80252
DC Field | Value | Language |
---|---|---|
dc.contributor | Department of Applied Biology and Chemical Technology | - |
dc.creator | Jiang, LJ | - |
dc.creator | Xie, C | - |
dc.creator | Lung, HL | - |
dc.creator | Lo, KW | - |
dc.creator | Law, GL | - |
dc.creator | Mak, NK | - |
dc.creator | Wong, KL | - |
dc.date.accessioned | 2019-01-30T09:14:27Z | - |
dc.date.available | 2019-01-30T09:14:27Z | - |
dc.identifier.uri | http://hdl.handle.net/10397/80252 | - |
dc.language.iso | en | en_US |
dc.publisher | Ivyspring International Publisher | en_US |
dc.rights | © Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. | en_US |
dc.rights | The following publication Jiang, L.J., Xie, C., Lung, H.L., Lo, K.W., Law, G.L., Mak, N.K., & Wong, K.L. (2018). EBNA1-targeted inhibitors : novel approaches for the treatment of Epstein-Barr virus-associated cancers. Theranostics, 8 (19), 5307-5319 is available at https://dx.doi.org/10.7150/thno.26823 | en_US |
dc.subject | EBNA1-targeted inhibitor | en_US |
dc.subject | Fluorescent probe | en_US |
dc.subject | EBV-associated cancers | en_US |
dc.subject | EBV | en_US |
dc.subject | EBNA1 | en_US |
dc.title | EBNA1-targeted inhibitors : novel approaches for the treatment of Epstein-Barr virus-associated cancers | en_US |
dc.type | Journal/Magazine Article | en_US |
dc.identifier.spage | 5307 | - |
dc.identifier.epage | 5319 | - |
dc.identifier.volume | 8 | - |
dc.identifier.issue | 19 | - |
dc.identifier.doi | 10.7150/thno.26823 | - |
dcterms.abstract | Epstein-Barr virus (EBV) infects more than 90% of humans worldwide and establishes lifelong latent infection in the hosts. It is closely associated with endemic forms of a wide range of human cancers and directly contributes to the formation of some. Despite its critical role in cancer development, no EBV-or EBV latent protein-targeted therapy is available. The EBV-encoded latent protein, Epstein-Barr nuclear antigen 1 (EBNA1), is expressed in all EBV-associated tumors and acts as the only latent protein in some of these tumors. This versatile protein functions in the maintenance, replication, and segregation of the EBV genome and can therefore serve as an attractive therapeutic target to treat EBV-associated cancers. In the last decades, efforts have been made for designing specific EBNA1 inhibitors to decrease EBNA1 expression or interfere with EBNA1-dependent functions. In this review, we will briefly introduce the salient features of EBNA1, summarize its functional domains, and focus on the recent developments in the identification and design of EBNA1 inhibitors related to various EBNA1 domains as well as discuss their comparative merits. | - |
dcterms.accessRights | open access | en_US |
dcterms.bibliographicCitation | Theranostics, 2018, v. 8, no. 19, p. 5307-5319 | - |
dcterms.isPartOf | Theranostics | - |
dcterms.issued | 2018 | - |
dc.identifier.isi | WOS:000450037900008 | - |
dc.identifier.eissn | 1838-7640 | - |
dc.description.validate | 201901 bcrc | - |
dc.description.oa | Version of Record | en_US |
dc.identifier.FolderNumber | OA_IR/PIRA | en_US |
dc.description.pubStatus | Published | en_US |
Appears in Collections: | Journal/Magazine Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Jiang_EBNA1-targeted_Inhibitors_Epstein-Barr.pdf | 1.33 MB | Adobe PDF | View/Open |
Page views
135
Last Week
1
1
Last month
Citations as of Apr 14, 2024
Downloads
119
Citations as of Apr 14, 2024
SCOPUSTM
Citations
38
Citations as of Apr 12, 2024
WEB OF SCIENCETM
Citations
36
Last Week
0
0
Last month
Citations as of Apr 18, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.